Skip to main content
. 2022 Feb;10(4):214. doi: 10.21037/atm-22-358

Figure 4.

Figure 4

TMB and cancer-associated mutations in tissue samples. (A,B) TMB among KRAS p.G12A (n=7), p.G12C (n=13), p.G12D (n=81), p.G12R (n=6), p.G12S (n=8), p.G12V (n=56), and KRAS other (n=1,333) alterations in tissue samples, removing the highest value (A) or removing the highest two values (B). (C) TMB between KRAS other (n=1,333) alterations and KRAS p.G12 (n=171) alteration in tissue samples. (D) TMB between EGFR mutation-negative patients (n=1,497) and EGFR mutation-positive patients (n=7) in tissue samples. TMB, tumor mutational burden; KRAS, Kirsten rat sarcoma; EGFR, epidermal growth factor receptor.